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Abstract
Aims/objective We aimed to assess the long-term effects of
post-transplant glycaemia on long-term survival after renal
transplantation.
Methods Study participants were 1,410 consecutive trans-
plant recipients without known diabetes who underwent an
OGTT 10 weeks post-transplant and were observed for a
median of 6.7 years (range 0.3–13.8 years). The HRs adjusted
for age, sex, traditional risk factors and transplant-related risk
factors were estimated.
Results Each 1 mmol/l increase in fasting plasma glucose (fPG)
or2 hplasmaglucose(2hPG) was associatedwith 11% (95%CI
−1%, 24%) and 5% (1%, 9%) increments in all-cause mortality
risk and 19% (1%, 39%) and 6% (1%, 12%) increments in
cardiovascular (CV) mortality risk, respectively. Including both
fPG and 2hPG in the multi-adjusted model the HR for 2hPG
remained unchanged, while the HR for fPG was attenuated
(1.05 [1.00, 1.11] and 0.97 [0.84, 1.14]). Compared with
recipients with normal glucose tolerance, patients with post-
transplant diabetes mellitus had higher all-cause and CV
mortality(1.54[1.09,2.17]and1.80[1.10,2.96]),whilepatients
with impaired glucose tolerance (IGT) had higher all-cause, but
not CV mortality (1.39 [1.01, 1.91] and 1.04 [0.62, 1.74]).
Conversely, impaired fasting glucose was not associated with
increased all-cause or CV mortality (0.79 [0.52, 1.23] and 0.76
[0.39, 1.49]). Post-challenge hyperglycaemia predicted death
from any cause and infectious disease in the multivariable
analyses (1.49 [1.15, 1.95] and 1.91 [1.09, 3.33]).
Conclusions/interpretation For predicting all-cause and CV
mortality, 2hPG is superior to fPG after renal transplanta-
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DOI 10.1007/s00125-011-2105-9tion. Also, early post-transplant diabetes, IGT and post-
challenge hyperglycaemia were significant predictors of
death. Future studies should determine whether an OGTT
helps identify renal transplant recipients at increased risk of
premature death.
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Abbreviations
2hPG 2 h plasma glucose after an OGTT
CV Cardiovascular
CMV Cytomegalovirus
fPG Plasma glucose after an overnight fast
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
NGT Normal glucose tolerance
PTDM Post-transplant diabetes mellitus
Introduction
Renal transplant recipients have an increased risk of
premature death, with cardiovascular disease (CVD),
malignancy and infectious disease being the predominant
causes of mortality [1]. Immunosuppressive therapy may
potentiate traditional pre-transplant risk factors [2], but
cannot fully explain the increased long-term mortality after
renal transplantation [3].
Hyperglycaemia is reported to be a risk marker for CVD
and cancer among healthy individuals without diabetes [4,
5]. Post-challenge hyperglycaemia is particularly associated
with increased all-cause, cardiovascular (CV) and cancer
mortality in the general population [5–7]. The impact of
hyperglycaemia on patient survival after renal transplanta-
tion is, however, unknown. Some studies indicate an
association between post-transplant diabetes mellitus
(PTDM) and mortality [8–10], whereas others do not [11,
12]. Renal transplant recipients may have normal fasting
plasma glucose (fPG) but at the same time elevated 2 h
plasma glucose (2hPG). Only half of individuals with new-
onset diabetes after renal transplantation are identified from
an fPG≥7.0 mmol/l [13], as compared with 70% in the
general population [14] and 80% in morbidly obese persons
[15]. In addition, approximately one out of five recipients
has impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG) 10 weeks after renal transplantation [16].
Thus, performing an OGTT in the early post-transplant
period may be important for the identification of renal
transplant patients with hyperglycaemia.
The aim of this study was to assess the long-term effects
of early post-transplant glycaemia on overall and cause-
specific mortality after renal transplantation.
Methods
Design and study population A total of 2,458 consecutive
patients received a renal transplant at our centre between
2 February 1995 and 19 October 2006. After the exclusion
of 1,048 patients because of re-transplantation, age
<18 years, early death, early graft loss, pre-existing diabetes
mellitus or failure to perform an OGTT, 1,410 patients were
included in this prospective cohort study (Fig. 1). The
participants were observed until either the primary endpoint
(death)wasreachedor31December2008(median[range]6.7
[0.3–13.8] years). Patients who developed PTDM (manifest
PTDM, n=58) before the scheduled OGTT did not complete
the test, while the remaining 1,352 first-time renal transplant
recipients underwent an OGTT 10 weeks (mean [SD] 71 [9]
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Fig. 1 The number of patients receiving their first kidney transplant
without pre-existing diabetes mellitus at the time of transplantation
(Tx). Re-transplant recipients were excluded. Failure to perform an
OGTT denotes patients who were transferred to local hospitals before
the scheduled OGTT at baseline 10 weeks after renal transplantation.
Patients who developed manifest diabetes during the first 10 weeks
after transplantation (Manifest PTDM) did not undergo an OGTT. A
total of 1,410 patients were included in the prospective cohort study
and 1,352 patients underwent an OGGT
1342 Diabetologia (2011) 54:1341–1349days) after renal transplantation. The participants gave
informed consent and the study was approved by the
regional ethics committee and was performed in accordance
with the Declaration of Helsinki [17].
Glucose measurements The OGTT was performed after an
overnight fast with patients instructed not to eat or drink, to
refrain from smoking and not to take any medication less
than 8 h before the test. Each patient drank 75 g of
anhydrous glucose dissolved in 250 ml of water. Blood
samples were drawn at 0 and 120 min. From May 1995 to
August 1996, glucose was measured in serum using a
glucose dehydrogenase method (Cobas Mira, Roche, Basel,
Switzerland). From September 1996 until December 2006
venous whole blood glucose was measured using the
Hemocue AB B-glucose Analyzer, Angelholm, Sweden.
The glucose measurements are presented as plasma (serum)
glucose [18]. Plasma glucose was calculated by multiplying
whole blood glucose with the constant factor of 1.11 [19].
Assessment of diabetes and glycaemia The current ADA
criteria were used to classify patients into the following
glucose categories: PTDM, fPG ≥7.0 mmol/l or 2hPG
≥11.1 mmol/l; IFG, fPG 5.6–6.9 mmol/l and 2hPG
<7.8 mmol/l; IGT, fPG <7.0 mmol/l and 2hPG 7.8–
11.0 mmol/l; and normal glucose tolerance (NGT), fPG
<5.6 mmol/l and 2hPG <7.8 mmol/l [20]. Patients were
also categorised as either post-challenge hyperglycaemia
defined as a 2hPG ≥7.8 mmol/l or normoglycaemia
defined as a 2hPG <7.8 mmol/l [20].
Immunosuppressive therapy Our immunosuppressive pro-
tocol has been described previously [13]. In summary, the
standard protocol from February 1995 to January 2000
consisted of prednisolone, ciclosporin A, azathioprine, and
thereafter the protocol included prednisolone, ciclosporin A
and mycophenolate. In most instances, tacrolimus was
given if ciclosporin A was withdrawn because of rejection,
toxicity or side effects.
Data registration and endpoints The following baseline
data were collected 10 weeks after renal transplantation:
recipient age,sex,BMI,fPG,2hPG,HbA1c, serum creatinine,
Cr-EDTA-measured glomerular filtration rate, serum lipids
and immunosuppressive medication. Friedewald’se q u a t i o n
was used to calculate LDL-cholesterol. We searched the
Norwegian Renal Registry [21] and the DataCor database
[22] to identify patients with pre-transplant CVD. Patients
were classified as having pre-transplant CVD if they
had: suffered a CV event (myocardial infarction, angina
pectoris, stroke/transient ischaemic attack or claudica-
tion); or had undergone a revascularisation procedure
(percutaneous coronary intervention or coronary artery
bypass graft surgery) or surgery on pre-cerebral arteries
or for peripheral vascular disease. Data on smoking
habits, pre-transplant renal status and hypertension were
collected from the Norwegian Renal Registry [21].
According to National Kidney Foundation Disease Out-
come Quality guidelines, hypertension was defined if patients
were using anti-hypertensive therapy within the first post-
transplant year or had a systolic blood pressure ≥140 mmHg
or a diastolic blood pressure ≥90 mmHg. Patients who did not
receive pre-transplant dialysis were encoded as pre-emptive
transplantation. Early cytomegalovirus (CMV) infection was
diagnosed in patients with at least one positive test for either
CMV-pp65 antigen in leucocytes or CMV-PCR in plasma
before baseline [23].
The study outcomes were all-cause and cause-specific
mortality after renal transplantation as defined by the
European Renal Association–European Dialysis and Trans-
plant Association causes of death codes: CV 11–18 and 21–
29; infection 31–43; malignancy 66–67; other diagnoses
(43–46, 51–53, 61–64, 69–73, 81–82); and unknown (0)
[24]. Nephrologists at 24 centres annually report data on all
Norwegian patients undergoing renal replacement therapy
to the Norwegian Renal Registry [21], from which numbers
and causes of deaths were retrieved. The numbers of death
were cross-checked with the official Norwegian National
Registry and the causes of death were encoded by
experienced local nephrologists.
Missing data Some variables in the data set had missing
data: hypertension (32%), smoking status (27%), total
cholesterol (10%), height (3%), weight (3%), creatinine
(3%) and CMV infection (1%). To compensate for missing
data, multiple imputation was used to generate ten iterations
for the variables with missing data, each containing 1,410
complete cases [25]. Both complete and incomplete
variables were used as predictors during the imputation
process. The variables used for multiple imputation
included: age, sex, donor age, donor status (living or
deceased), height, weight, creatinine, use of ciclosporin A,
early CMV infection, early hepatitis C virus infection, total
cholesterol, fPG, 2hPG, HbA1c, early rejection, hyperten-
sion, primary diagnosis of renal disease (glomerulonephritis,
pyelonephritis, polycystic kidney disease, nephrosclerosis,
other diagnoses), pre-transplant renal status (haemodialy-
sis, peritoneal dialysis, pre-emptive transplantation), hu-
man leucocyte antigen (HLA)-DR mismatch (none, one,
two), smoking status (never, former or current), cause of
death (CVD, malignancy, infection, other, unknown),
survival time (months). Variables not normally distributed
were logarithmically transformed (fPG, 2hPG and creati-
nine). Statistical analyses were first performed on each
imputed data set, and thereafter pooled to achieve a single
variable estimate.
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sented as mean (SD) or frequency (%). The 1,352 patients
who underwent the OGTT were dichotomised to have post-
challenge hyperglycaemia (2hPG ≥7.8 mmol/l) or normo-
glycaemia. Differences between groups were analysed
using independent samples t test for continuous data and
Fisher’s exact test for categorical data. Associations
between fPG and 2hPG were analysed using non-
parametric correlations (Spearman’s ρ). Kaplan–Meier plots
and logrank test were used to analyse crude cumulative
survival for the various ADA categories.
Hazard ratios and corresponding 95% CIs were estimated
using Cox proportional hazard regression models. Glycaemia
was included as either a continuous explanatory variable or a
categorical variable. Continuous explanatory variables were
fPG and 2hPG. Categorical variables were: NGT=reference;
IFG; IGT; PTDM; and post-challenge hyperglycaemia,
yes/no. Patients with manifest PTDM (n=58) before the
scheduled OGTT were included only in the analyses with
glucose categories as explanatory variables. Also, an
interaction term between fPG and 2hPG was included.
We fitted three multiple Cox regression models. In
model 1 we adjusted for age and sex. In model 2 we
further adjusted for traditional risk factors: BMI; creatinine;
pre-transplant CVD; total cholesterol; hypertension; and
smoking status [1–3, 10]. In model 3 we included
additional adjustments for transplant-related risk factors:
donor status; pre-emptive transplantation; CMV infection;
early rejection; and usage of ciclosporin A [2, 3, 11]. The
assumption of linearity was assessed by fitting multifrac-
tional models, which allows for several types of non-
linearity, and testing for the best fit [26].
Model discrimination between predicted and estimated
risk was assessed using Harrell’s concordance index
(c-statistic) [27, 28]. A result was considered to be
statisticallysignificantwhenp<0.05. Statistical analyses were
conducted with the use of Stata 11.0 (StataCorp, College
Station, TX, USA) and PASW 18.0 (Chicago, IL, USA).
Results
Out of 1,410 recipients included in the prospective study, a
total of 638 (45%) had NGT, 217 (16%) had IFG, 313
(22%) had IGT and 242 (17%) had PTDM.
Demographic and clinical characteristics of the patients
who underwent an OGTT (n=1,352) according to the
presence or absence of post-challenge hyperglycaemia are
presented in Table 1. The recipients with a 2hPG
≥7.8 mmol/l were significantly older, had less favourable
kidney function and were more likely to have a history of
smoking, pre-transplant CVD, CMV infection and rejection
than those with 2hPG <7.8 mmol/l. Unadjusted all-cause
and CV mortality HRs of prevalent risk factors inherent to
the transplant population are presented in Table 2.
A totalof282 (20%) ofthe 1,410 recipientsdiedduringthe
study period: 79 (12%) of the patients with NGT, 31 (14%) of
the patients with isolated IFG, 90 (29%) of the patients with
IGT, and 82 (34%) of the patients with PTDM (p<0.001). A
total of 120 (42%) patients died from CVD, 65 (23%) from
malignancy, 67 (24%) from infectious diseases, 17 (6%)
from other causes and 13 (5%) from unknown causes.
Septicaemia and bacterial pneumonia accounted for 57% and
31% of the infectious deaths, respectively.
Mortalityaccordingtoglucoseasacontinuousvariable Both
fPG and 2hPG were associated with increased all-cause and
CV mortality risk in the unadjusted Cox regression analyses
(Tables 3 and 4). After adjustments for confounders, the
impact of fPG became statistically non-significant, while
2hPG remained a significant predictor of overall mortality
risk (Table 3). In the multivariable cause-specific Cox
regression analyses, both fPG and 2hPG remained associ-
ated with increased risk of CV death (Table 4). The fPG
and 2hPG were correlated (r=0.59, p<0.001), but there was
no statistically significant interaction between fPG and
2hPG (p=0.527). When both 2hPG and fPG were included
in the multivariable model 3, only 2hPG was found to be a
predictor of all-cause mortality (2hPG, HR 1.05 [95% CI
1.00, 1.11] p=0.038; fPG, HR 0.97 [95% CI 0.84, 1.14]
p=0.740). For all the regressions analyses, a linear model
was the best fit for the continuous glucose measurements
(data not shown).
Mortality and glucose as categorical variables Cumulative
mortality according to glucose category is shown in Fig. 2.
The logrank test indicated a significant difference in
mortality between the subgroups (p<0.001). Recipients
with PTDM, IGT or post-challenge hyperglycaemia at
baseline had an approximately twofold unadjusted in-
creased death risk compared with those with NGT or post-
challenge normoglycaemia (Table 3). The overall mortality
risk was attenuated after multiple adjustments in Cox
models 1–3, but remained statistically significant in all the
multivariable analyses. Conversely, IFG failed to show any
association with mortality (Tables 3 and 4).
Table 4 shows that post-challenge hyperglycaemia was
associated with an approximately twofold increased risk of
death from CV disease, malignancy and infectious disease.
PTDM was associated with a nearly threefold increased
risk from CVD, while IGT was associated with a twofold
increased risk of infectious death. After multivariable
adjustments, PTDM remained associated with a twofold
increased risk of CV death, whilst post-challenge hyper-
glycaemia, but not IGT, remained associated with a nearly
1344 Diabetologia (2011) 54:1341–1349twofoldhighermortalityriskfrominfectiousdisease(Table4).
Including the various glucose variables into model 3 had
minimal effect on overall and CV mortality with an increase
in c-statistic of less than 0.01 (data not shown).
Of the 184 recipients with new-onset PTDM diagnosed
from an OGTT, 92 (50%) were diagnosed from an fPG
≥7.0 mmol/l and an equal number of patients were
diagnosed from an isolated 2hPG ≥11.1 mmol/l (n=92),
whereas 63 (34%) patients fulfilled both the criteria. Mean
fPG for recipients with an isolated 2hPG ≥11.1 mmol/l was
5.9 (0.69)mmol/l. Compared with recipients without
PTDM, the multi-adjusted HRs of recipients diagnosed
from fPG ≥7 . 0m m o l / la n d2 h P G≥11.1 mmol/l were
1.49 (95% CI 1.00, 2.23) and 1.22 (0.80, 1.86).
Discussion
The main finding of this large single-centre study of renal
transplant recipients was that as a predictor of long-term
mortality, post-challenge 2hPG measured early after renal
transplantation was superior to, and independent of, fPG,
even after adjustments for confounding risk factors. Each
1 mmol/l increment in 2hPG was associated with a 5%
(95% CI 1%, 9%) increased risk of death from any cause
and 6% (95% CI 1%, 12%) increased risk of death from CV
Table 2 Unadjusted HR risk estimates by Cox proportional regres-
sion analyses for all-cause and CV mortality
Variable Overall mortality CV mortality
HR (95% CI) HR (95% CI)
Age (years) 1.06 (1.05, 1.07) 1.07 (1.06, 1.09)
Male 1.31 (1.01, 1.69) 1.66 (1.09, 2.52)
BMI (kg/m
2) 0.97 (0.94, 1.01) 1.01 (0.96, 1.06)
Creatinine (μmol/l) 1.00 (1.00, 1.01) 1.01 (1.00, 1.01)
Pre-transplant CVD 2.07 (1.59, 2.71) 2.56 (1.73, 3.79)
Total cholesterol (mmol/l) 1.01 (0.92, 1.10) 0.96 (0.84, 1.09)
Hypertension 0.66 (0.48, 0.92) 0.88 (0.46, 1.67)
Active or former smoker 1.17 (0.79, 1.74) 1.28 (0.71, 2.32)
Deceased donor 2.39 (1.83, 3.12) 2.77 (1.82, 4.23)
Pre-emptive transplantation 0.62 (0.46, 0.84) 0.58 (0.36, 0.93)
CMV infection 1.62 (1.26, 2.07) 1.91 (1.29, 2.84)
Early rejection 1.02 (0.81, 1.30) 1.31 (0.92, 1.88)








n (%) 1,352 863 (64) 489 (36) –
Age (years) 51 (15) 49 (15) 55 (14) <0.001
Male, n (%) 892 (66) 564 (65) 328 (67) 0.550
BMI (kg/m
2) 24.3 (3.6) 24.2 (3.5) 24.6 (3.7) 0.062
Obese (BMI ≥30 kg/m
2), n (%) 87 (7) 51 (6) 36 (8) 0.300
Creatinine (μmol/l) 132 (41) 129 (36) 137 (47) 0.002
GFR (ml min
−1 1.73 m
−2) 53.7 (14.7) 54.5 (14.1) 52.0 (15.8) 0.006
Pre-transplant CVD, n (%) 216 (16) 116 (13) 100 (20) 0.001
Total cholesterol (mmol/l) 6.53 (1.50) 6.51 (1.45) 6.57 (1.59) 0.519
HDL-cholesterol (mmol/l) 1.55 (0.49) 1.59 (0.49) 1.46 (0.46) <0.001
Triacylglycerol (mmol/l) 2.14 (2.17) 2.03 (2.45) 2.38 (1.43) 0.008
LDL-cholesterol (mmol/l) 4.02 (1.53) 4.01 (1.61) 4.05 (1.36) 0.657
Hypertension, n (%) 745 (83) 487 (84) 258 (83) 0.925
Active or former smoker, n (%) 603 (61) 393 (57) 210 (69) 0.001
Deceased donor, n (%) 745 (55) 427 (50) 318 (65) <0.001
Months on dialysis 15 (13) 14 (14) 15 (11) 0.578
Pre-emptive transplantation, n (%) 328 (24) 214 (25) 114 (23) 0.553
CMV infection, n (%) 740 (55) 445 (52) 295 (61) 0.002
Early rejection, n (%) 490 (36) 277 (32) 213 (44) <0.001
Prednisolone dose (mg/day) 13.1 (5.2) 12.5 (4.6) 14.3 (6.0) <0.001
Use of ciclosporin A, n (%) 1,137 (90) 732 (90) 405 (90) 0.768
Ciclosporin A trough level (μg/l) 219 (76) 212 (73) 233 (81) <0.001
Use of tacrolimus, n (%) 124 (10) 78 (10) 46 (10) 0.767
Tacrolimus trough level (μg/l) 9.7 (3.3) 9.4 (3.3) 10.2 (3.2) 0.194
Table 1 Baseline characteristics
of the study population according
to post-challenge glycaemia
Data are given as mean (SD) or
frequency (%)





denotes patients who received a
kidney transplant before starting
dialysis
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Variable Unadjusted HR (95% CI) Multivariable HR (95% CI)
Model 1 Model 2 Model 3
Glucose category
Normal glucose tolerance 1.00 1.00 1.00 1.00
Impaired fasting glucose 0.74 (0.49, 1.13) 0.77 (0.50, 1.17) 0.77 (0.51, 1.18) 0.79 (0.52, 1.23)
Impaired glucose tolerance 1.78 (1.32, 2.42)* 1.43 (1.05, 1.94)* 1.42 (1.05, 1.94)* 1.39 (1.01, 1.91)*
Post-transplant diabetes mellitus 2.03 (1.49, 2.77)* 1.51 (1.10, 2.07)* 1.54 (1.12, 2.13)* 1.54 (1.09, 2.17)*
p values for trend <0.001 0.001 0.002 0.006
Harrell’s concordance index 0.597 0.738 0.759 0.757
Level of 2hPG
Post-challenge normoglycaemia 1.00 1.00 1.00 1.00
Post-challenge hyperglycaemia 1.98 (1.55, 2.54)* 1.53 (1.19, 1.97)* 1.55 (1.21, 2.00)* 1.49 (1.15, 1.95)*
Harrell’s concordance index 0.583 0.737 0.755 0.759
fPG
fPG (mmol/l) 1.13 (1.03, 1.24)* 1.10 (1.00, 1.21) 1.12 (1.01, 1.24)* 1.11 (0.99, 1.24)
Harrell’s concordance index 0.538 0.734 0.750 0.755
2hPG
2hPG (mmol/l) 1.08 (1.05, 1.12)* 1.04 (1.01, 1.08)* 1.05 (1.01, 1.09)* 1.05 (1.01, 1.09)*
Harrell’s concordance index 0.594 0.742 0.754 0.757
Model 1 is adjusted for age and sex. Model 2 is additionally adjusted for traditional risk factors: BMI; creatinine; pre-transplant CVD; total
cholesterol; hypertension; and smoking status. Model 3 is additionally adjusted for transplant-related risk factors: donor status; pre-emptive
transplantation; CMV infection; early rejection; and use of ciclosporin A
*p<0.05
Table 4 HR estimated by Cox regression analyses for CV death, death from malignancy and from infectious disease according to plasma glucose
(as categorical or continuous variables)
Variable Unadjusted HR (95% CI) Multivariable HR (95% CI) (model 3)
CVD Malignancy Infection CVD Malignancy Infection
Glucose category
Normal glucose tolerance 1.00 1.00 1.00 1.00 1.00 1.00
Impaired fasting glucose 0.73 (0.37, 1.41) 0.94 (0.42, 2.08) 0.44 (0.16, 1.17) 0.76 (0.39, 1.49) 0.97 (0.42, 2.00) 0.50 (0.18, 1.37)
Impaired glucose tolerance 1.52 (0.93, 2.50) 1.73 (0.92, 3.25) 1.89 (1.05, 3.41)* 1.04 (0.62, 1.74) 1.37 (0.71, 2.64) 1.75 (0.92, 3.34)
Post-transplant diabetes mellitus 2.72 (1.73, 4.29)* 1.80 (0.93, 3.48) 1.45 (0.75, 2.82) 1.80 (1.10, 2.96)* 1.36 (0.65, 2.83) 1.37 (0.66, 2.86)
p values for trend <0.001 0.138 0.011 0.023 0.687 0.055
Harrell’s concordance index 0.627 0.572 0.595 0.782 0.736 0.816
Level of 2hPG
Post-challenge normoglycaemia 1.00 1.00 1.00 1.00 1.00 1.00
Post-challenge hyperglycaemia 2.00 (1.36, 2.93)* 1.79 (1.07, 2.97)* 2.07 (1.24, 3.46)* 1.34 (0.89, 2.00) 1.34 (0.78, 2.30) 1.91 (1.09, 3.33)*
Harrell’s concordance index 0.593 0.572 0.568 0.779 0.738 0.817
fPG
fPG (mmol/l) 1.21 (1.06, 1.37)* 1.17 (0.98, 1.40) 0.95 (0.75, 1.20) 1.19 (1.01, 1.39)* 1.16 (0.94, 1.44) 0.95 (0.73, 1.24)
Harrell’s concordance index 0.562 0.557 0.512 0.777 0.732 0.810
2hPG
2hPG (mmol/l) 1.11 (1.06, 1.16)* 1.05 (0.98, 1.13) 1.06 (1.00, 1.14) 1.06 (1.01, 1.12)* 1.01 (0.93, 1.09) 1.05 (0.97, 1.14)
Harrell’s concordance index 0.626 0.573 0.556 0.780 0.734 0.813
Model 3 is adjusted for age, sex, BMI, creatinine, pre-transplant CVD, total cholesterol, hypertension, smoking status, donor status, pre-emptive
transplantation, CMV infection, early rejection and use of ciclosporin A
*p<0.05
1346 Diabetologia (2011) 54:1341–1349disease. In addition, our findings are the first to indicate that
renal transplant recipients with IGT have lower long-term
chance of survival than those with NGT.
Glucose measurements as continuous variables This study
demonstrates an independent continuous relationship
between 2hPG and long-term mortality in a renal transplant
population without known diabetes. These findings are in
accordance with two previous community-based cohort
studies of non-diabetic persons of comparable age [6, 29].
Our results also partly support the findings from a
population-based prospective cohort of more than 10,000
adult men and women demonstrating a continuous positive
relationship between non-diabetic hyperglycaemia and
mortality [30]. In our study the association between fPG
and mortality became statistically non-significant after
adjustments for transplant-related risk factors. Some studies
have reported a J-shaped relationship between fPG as a
continuous variable and both overall and CV mortality,
whereas a linear relationship best described the association
between 2hPG and overall and CV mortality [30, 31]. We
cannot completely rule out the possibility that a non-linear
relationship between fPG and mortality might have influ-
enced the Cox proportional hazard risk. However, by fitting
our models using multifractional models, no non-linear
model outperformed a standard linear model in our sets of
data.
Post-challenge hyperglycaemia and glucose categories Re-
cipients with post-challenge hyperglycaemia, PTDM and
IGT had an increased overall mortality risk. Our findings
confirm the results of two large cohort studies that
demonstrated that PTDM, diagnosed by Medicare claims
or required treatment for hyperglycaemia, is associated with
reduced patient survival [8, 10]. We now extend this
conclusion to PTDM diagnosed by fasting glucose as well
as to PTDM and IGT diagnosed by an OGTT.
Our findings also concur with those from two large meta-
analysesaddressingthe impactofIFGandIGTonmortalityin
non-transplant European populations that found that IGT is
superior to IFG in predicting all-cause and CV mortality and
from five Asian populations that found that IGT but not IFG
was associated with all-cause and CV mortality [7, 32]. In
contrast to the latter analysis, we diagnosed patients with
isolated IFG (fPG of 5.6–6.9 mmol/l) (excluding concomi-
tant IGT), which might have reduced the mortality risk in
this group. Nevertheless, IFG was not associated with death
after the inclusion of all recipients with an fPG of 5.6–
6.9 mmol/l in the present study (data not shown).
In further contrast with our study, the previous studies
implemented the criteria of the WHO for IFG (fPG 6.1–
6.9 mmol/l) [33]. However, our results were largely
unchanged when we reclassified the glucose categories
according to the WHO criteria (data not shown). Partly in
contrast with our findings, one large Australian prospective
study showed that both isolated IFG (WHO criteria) and
IGT were independent predictors of all-cause and CV
mortality [34]. Our findings indicate persons with increased
risk of death, but do not necessarily imply that lowering of
glucose excursions would reduce this risk. In a recently
published study of non-transplanted persons with IGT and
either established CVD or known risk factors for CVD, a
5-year period of treatment with nateglinide did not
influence the incidence of CVD. In this study, however,
the participants had a lower mortality risk as compared with
a transplant population.
Whether glucose-lowering therapy in renal transplant
recipients with either IGT or PTDM is associated with lower
long-term morbidity or mortality remains to be shown.
In the cause-specific analysis, PTDM was associated
with increased mortality from CVD whilst post-challenge
hyperglycaemia predicted increased mortality from infec-
tious disease. The reduction in deaths from infectious
disease is considered one of the major improvements in
short-term mortality outcome after renal transplantation
during the recent decades, and the predominant cause of
infection beyond 6 months post-transplant is bacterial rather
than viral [1]. In the present study, 90% of the infectious
deaths were caused by either bacterial pneumonia or
septicaemia. However, our finding of a possible relation-
ship between post-challenge hyperglycaemia and long-term
mortality from infectious diseases needs verification and
should be interpreted with care.
Strengths and limitations The inclusion of a large number
of consecutively included non-diabetic renal transplant
recipients at the single transplant centre in Norway reduced
the possibility of sample selection bias and increased the
internal validity of the study. Only 10% of the eligible
patients were unable to participate. The study population
Fig. 2 Cumulative mortality for recipients with NGT (solid black
line), IFG (dashed black line), IGT (dashed grey line) and PTDM
(solid grey line)
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results cannot be extended to populations of other ethnic-
ities. However, comparable results for PTDM have been
reported in two other studies that included individuals of
multiple races and ethnicities [8, 10].
The OGTT has poor reproducibility and a repeated test
diagnostic of diabetes is recommended by the current
guidelines [20]. However, according to the WHO an
epidemiological diagnosis of diabetes can be based on a
single OGTT or fPG [35]. Furthermore, although the OGTT
is more time consuming and has a higher intraindividual
coefficient of variance compared with fasting plasma
glucose, it is a more sensitive test for diagnosing PTDM
and IGT after renal transplantation [13, 36].
To account for missing data on hypertension (32%),
smoking status (27%) and total cholesterol (10%), we
performed ten iterations of multiple imputations. Also, the
prognostic effect of 2hPG on overall mortality was
attenuated after adjustment for age and sex, but was largely
unchanged after further adjustments for both traditional and
transplant-related risk factors. Thus, the imputed covariates
contributed little to the prognostic effect of early post-
transplant glucose levels on long-term mortality.
The estimated outcomes coincided with the observed
mortality in this study (multi-adjusted c-statistics: all-cause
>75% and CV mortality >77%). The additional effect of
including the various glucose variables in the multi-
adjusted models was, however, minimal. Nevertheless,
early post-transplant glycaemia remained an independent
predictor of both all-cause and CV mortality.
We used fPG and 2hPG as diagnostic criteria for
diabetes without including the recently introduced ADA
criteria of HbA1c ≥6.5% [20]. The diagnostic value of
HbA1c in patients with end-stage renal disease awaiting
renal transplantation is poor, possibly because of uraemia,
usage of erythropoietin and dialysis [37]. In the early post-
transplant period haemoglobin levels stabilise and normal-
ised levels of erythropoietin and haematocrit have been
reported as early as at 2 months post-transplant [38].
However, blood loss related to surgical procedures and
subsequent inflammation, immunosuppressant agents caus-
ing bone marrow suppression and abrupt cessation of
erythropoietin are among the factors that may affect HbA1c
levels early after kidney transplantation [38].The usage of
HbA1c as a diagnostic criterion might therefore not apply in
the early post-transplant period.
Conclusions
This study indicates that 2hPG, when measured early after
renal transplantation, is superior to fPG in predicting long-
term all-cause and CV mortality. It also demonstrates that
PTDM predicts both all-cause and CV mortality, whereas
IGT predicts all-cause, but not CV mortality and finally that
post-challenge hyperglycaemia predicts all-cause mortality
and death from infectious disease. Post-challenge hyper-
glycaemia may be a predictor of long-term outcome in renal
transplant patients, and an OGTT might provide a method
to identify renal transplant recipients with increased risk of
premature death.
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